Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) traded up 10.8% during trading on Monday . The company traded as high as $8.90 and last traded at $8.9630. Approximately 828,992 shares traded hands during trading, a decline of 28% from the average session volume of 1,155,742 shares. The stock had previously closed at $8.09.
Analyst Ratings Changes
A number of research firms recently weighed in on DNA. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. Wall Street Zen downgraded Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Ginkgo Bioworks has a consensus rating of “Reduce” and an average price target of $8.50.
Read Our Latest Analysis on DNA
Ginkgo Bioworks Stock Down 0.9%
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.18). The company had revenue of $19.00 million during the quarter, compared to analysts’ expectations of $42.93 million. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Prescott Group Capital Management L.L.C. bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth $4,503,000. UBS Group AG raised its holdings in shares of Ginkgo Bioworks by 86.4% in the fourth quarter. UBS Group AG now owns 489,418 shares of the company’s stock valued at $4,067,000 after acquiring an additional 226,861 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Ginkgo Bioworks by 28,457.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 228,744 shares of the company’s stock worth $1,901,000 after acquiring an additional 227,943 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Ginkgo Bioworks by 66.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 50,273 shares of the company’s stock worth $418,000 after acquiring an additional 20,005 shares during the period. Finally, Shay Capital LLC grew its holdings in Ginkgo Bioworks by 6.2% during the 2nd quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock worth $218,000 after acquiring an additional 1,124 shares in the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
Featured Articles
- Five stocks we like better than Ginkgo Bioworks
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
